Which mood‑stabilizing medications are safe to use during pregnancy for a woman with bipolar disorder?

Mood Stabilizers Safe During Pregnancy for Bipolar Disorder

For women with bipolar disorder during pregnancy, lamotrigine and lithium (after the first trimester) are the safest mood stabilizers, while valproate and carbamazepine must be avoided due to high teratogenicity risk. Atypical antipsychotics like quetiapine and olanzapine are also reasonable options, and importantly, untreated bipolar disorder poses greater risks to both mother and fetus than appropriately managed pharmacotherapy 1, 2, 3.

Medications to AVOID

Valproate is contraindicated in women of childbearing potential and during pregnancy due to:

• Major congenital malformations 2, 4
• Developmental delay and lower IQ in offspring 2
• Increased risk of autism spectrum disorder 2
• Neural tube defects 4

Carbamazepine should be avoided due to documented teratogenicity risk and association with major congenital malformations 2, 4, 3.

Safest First-Line Options

Lamotrigine

Lamotrigine appears to be one of the safest antiepileptic mood stabilizers for pregnancy 2, 4:

• Most favorable safety profile among antiepileptic drugs 2, 4
• Low recurrence rate during postpartum (7.9%) when continued 5
• Safe during lactation 2
• Recurrence rate of 41.2% during pregnancy in limited data 5

Lithium

Lithium is a viable option, particularly after the first trimester 2, 4, 3:

• Approved by FDA for bipolar disorder down to age 12 years 6
• Use during second and third trimester appears safe 2
• Recurrence rate of 22.7% during pregnancy and 20.3% postpartum 5
• Remains the gold standard for acute and maintenance treatment despite declining use 3, 7
• Requires close monitoring of levels during pregnancy due to changing renal clearance 3

Atypical Antipsychotics

Quetiapine and olanzapine show favorable safety profiles 1, 5, 3:

• Olanzapine: 11.7% recurrence rate postpartum, no episodes during pregnancy in limited data (n=6) 5
• Quetiapine: 33.3% recurrence rate postpartum 5
• Both medications demonstrated better neonatal outcomes than untreated bipolar disorder 1
• Lurasidone also shows promise with favorable outcomes comparable to lamotrigine and other atypicals 1

Aripiprazole is FDA-approved for acute mania in adults and represents another atypical antipsychotic option 6, 3.

Critical Clinical Considerations

Risk of Untreated Bipolar Disorder

Discontinuing treatment poses significant risks 8, 1:

• Increased risk of spontaneous abortion 8
• Increased risk of preterm birth 8
• Worse mental health outcomes and functional impairment in the pregnant individual 8
• Higher rates of premature delivery and low birth weight compared to treated patients 1

Postpartum Period

The postpartum period represents extremely high risk for relapse 3:

• Risk is more than twofold lower with adequate pharmacological prophylaxis 3
• Lamotrigine shows particularly low postpartum recurrence (7.9%) 5
• Valproate has unacceptably high postpartum recurrence (70.6%) and should not be used 5

Treatment Algorithm

Preconception planning:

• Switch from valproate or carbamazepine to lamotrigine or lithium 2, 3
• Optimize dose of safer medication before conception 3

During pregnancy:

• Continue lamotrigine throughout pregnancy if already stable 2, 5
• Consider lithium after first trimester if needed for severe illness 2, 3
• Use atypical antipsychotics (quetiapine, olanzapine, lurasidone) as alternatives 1, 5
• Monitor closely for mood symptoms and medication levels 3

Postpartum:

• Maintain or resume mood stabilizer immediately after delivery 3
• Create written relapse prevention plan including medication strategy 3
• Ensure adequate sleep and circadian rhythm stability 3
• Lamotrigine and valproate are safe during lactation, though valproate should not be used due to pregnancy risks 2

Common Pitfalls

Do not routinely discontinue all medications upon pregnancy confirmation - this increases relapse risk substantially and untreated bipolar disorder carries its own fetal risks 8, 1.

Do not use valproate even if the patient has been stable on it - the teratogenic risks are too high and alternatives exist 2, 4, 3.

Do not assume all mood stabilizers have equal safety profiles - there are significant differences, with lamotrigine and lithium (after first trimester) being considerably safer than valproate and carbamazepine 2, 4.